Sinovac Biotech’s Hand, Foot and Mouth Vaccine Succeeds in Phase III Trial
Sinovac Biotech, a vaccine maker headquartered in Beijing, reported positive, though preliminary top-line data from the Phase III clinical trial for its Enterovirus 71 vaccine, a human innoculation that protects against hand, foot and mouth disease. The vaccine, which was administered to infants from 6 to 35 months, produced an efficacy of 95.4%. More details.... Stock Symbol: (NSDQ: SVA) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here